AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 May 2025 04:00 PM
RNS
Director/PDMR Shareholding
01 May 2025 03:00 PM
RNS
Total Voting Rights
29 Apr 2025 07:10 AM
RNS
Fixed-duration Calquence recommended in EU for CLL
29 Apr 2025 07:05 AM
RNS
Update on CAPItello-280 Phase III trial
29 Apr 2025 07:00 AM
RNS
1st Quarter Results
22 Apr 2025 07:00 AM
RNS
Enhertu combination improved PFS in 1L HER2+ mBC
11 Apr 2025 05:30 PM
RNS
Result of AGM
04 Apr 2025 07:05 AM
RNS
Imfinzi approved in EU for AEGEAN
04 Apr 2025 07:00 AM
RNS
Enhertu approved in EU in post-ET breast cancer
01 Apr 2025 03:00 PM
RNS
Total Voting Rights
31 Mar 2025 07:05 AM
RNS
Calquence recommended for EU approval in 1L MCL
31 Mar 2025 07:00 AM
RNS
Imfinzi approved in the US for bladder cancer
21 Mar 2025 10:58 AM
RNS
AZN invests $2.5bn in Beijing R&D & manufacturing
17 Mar 2025 07:10 AM
RNS
Eneboparatide Phase III trial met primary endpoint
17 Mar 2025 07:05 AM
RNS
Imfinzi approved in EU for limited-stage SCLC
17 Mar 2025 07:00 AM
RNS
AstraZeneca to acquire EsoBiotec
12 Mar 2025 06:00 PM
RNS
Holding(s) in Company
07 Mar 2025 03:00 PM
RNS
Director/PDMR Shareholding
07 Mar 2025 11:00 AM
RNS
Notice of AGM
07 Mar 2025 07:00 AM
RNS
Imfinzi improved EFS in early-stage gastric cancer
06 Mar 2025 03:00 PM
RNS
Director/PDMR Shareholding
05 Mar 2025 03:00 PM
RNS
Director/PDMR Shareholding
03 Mar 2025 03:00 PM
RNS
Total Voting Rights
03 Mar 2025 07:00 AM
RNS
Imfinzi recommended for EU approval for AEGEAN
28 Feb 2025 01:00 PM
RNS
Enhertu recommended in EU in post-ET breast cancer
26 Feb 2025 07:00 AM
RNS
Camizestrant improved PFS in 1L HR+ breast cancer
19 Feb 2025 07:00 AM
RNS
Filing of Form 20-F with SEC
18 Feb 2025 02:00 PM
RNS
Holding(s) in Company
18 Feb 2025 11:00 AM
RNS
Annual Financial Report
18 Feb 2025 07:00 AM
RNS
Directorate Change
06 Feb 2025 07:00 AM
RNS
Final Results
03 Feb 2025 05:00 PM
RNS
Total Voting Rights
03 Feb 2025 07:00 AM
RNS
Imfinzi recommended for EU approval for LS-SCLC
28 Jan 2025 07:00 AM
RNS
Enhertu approved in US for breast cancer post ET
20 Jan 2025 07:00 AM
RNS
Dato-DXd approved in US for HR+ breast cancer
17 Jan 2025 07:00 AM
RNS
Calquence combination approved in US for 1L MCL
02 Jan 2025 03:00 PM
RNS
Total Voting Rights
24 Dec 2024 07:00 AM
RNS
Dato-DXd NSQ NSCLC application withdrawn in EU
23 Dec 2024 07:00 AM
RNS
Tagrisso approved in EU based on LAURA trial
16 Dec 2024 07:00 AM
RNS
Directorate Change
05 Dec 2024 07:00 AM
RNS
Imfinzi approved in US for limited-stage SCLC
04 Dec 2024 01:45 PM
RNS
AstraZeneca appoints Iskra Reic EVP International
02 Dec 2024 03:05 PM
RNS
Block listing Interim Review
02 Dec 2024 03:00 PM
RNS
Total Voting Rights
25 Nov 2024 07:00 AM
RNS
Truqap improved rPFS in advanced prostate cancer
20 Nov 2024 04:00 PM
RNS
Director/PDMR Shareholding
18 Nov 2024 07:00 AM
RNS
Tagrisso recommended for EU approval - LAURA
15 Nov 2024 02:00 PM
RNS
Director/PDMR Shareholding
15 Nov 2024 10:00 AM
RNS
Director/PDMR Shareholding
13 Nov 2024 04:00 PM
RNS
Director/PDMR Shareholding

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings